Literature DB >> 10907726

Chronic supranigral infusion of BDNF in normal and MPTP-treated common marmosets.

R K Pearce1, S Costa, P Jenner, C D Marsden.   

Abstract

BDNF or vehicle were administered by unilateral supranigral infusion in normal and chronically lesioned MPTP-treated common marmosets (Callithrix jacchus) for four weeks and locomotor activity, disability and response to apomorphine were assessed with nigral TH, GFAP and GAD immunoreactivity and striatal [3H]mazindol autoradiography. Selective contraversive orientation and ipsilateral neglect evolved in MPTP-treated marmosets receiving BDNF with no significant difference in disability or locomotor activity when compared to the vehicle-infused group. Apomorphine produced an ipsiversive rotational bias in BDNF-treated animals. In normal animals infused with BDNF contralateral neglect, ipsiversive turning, postural instability and ataxia rapidly evolved. In MPTP-treated marmosets BDNF caused increased ipsilateral striatal [3H]mazindol binding with increased somatic size and staining intensity in GAD-immunoreactive cells and a 10-20% loss of nigral TH-immunoreactive cells with increased GFAP staining. In normal common marmosets, both vehicle and BDNF infusion decreased nigral TH-immunoreactivity. Chronic supranigral infusion of BDNF alters motor behaviour and spatial attention in MPTP-treated marmosets which may reflect altered function in residual nigral dopaminergic neurons and brainstem GABAergic neurons and in normal animals produces behavioural and histological signs of nigrostriatal hypofunction.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10907726     DOI: 10.1007/s007020050188

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  2 in total

Review 1.  Neurotrophin Signaling and Stem Cells-Implications for Neurodegenerative Diseases and Stem Cell Therapy.

Authors:  Subrata Pramanik; Yanuar Alan Sulistio; Klaus Heese
Journal:  Mol Neurobiol       Date:  2016-11-05       Impact factor: 5.590

2.  Azilsartan ameliorates apoptosis of dopaminergic neurons and rescues characteristic parkinsonian behaviors in a rat model of Parkinson's disease.

Authors:  Qing Gao; Zhou Ou; Teng Jiang; You-Yong Tian; Jun-Shan Zhou; Liang Wu; Jian-Quan Shi; Ying-Dong Zhang
Journal:  Oncotarget       Date:  2017-04-11
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.